Cytomegalovirus in Children Undergoing Haematopoietic Stem Cell Transplantation: a Diagnostic and Therapeutic Approach to Antiviral Resistance

Overview

Journal Front Pediatr

Specialty Pediatrics

Date 2023 Jun 16

PMID 37325366

Authors

Jocelyn Hume

Emma L Sweeney

Kym Lowry

Chris Fraser

Julia E Clark

David M Whiley

Adam D Irwin

Affiliations

Soon will be listed here.

Abstract

Cytomegalovirus (CMV) is a ubiquitous virus which causes a mild illness in healthy individuals. In immunocompromised individuals, such as children receiving haematopoietic stem cell transplantation, CMV can reactivate, causing serious disease and increasing the risk of death. CMV can be effectively treated with antiviral drugs, but antiviral resistance is an increasingly common complication. Available therapies are associated with adverse effects such as bone marrow suppression and renal impairment, making the choice of appropriate treatment challenging. New agents are emerging and require evaluation in children to establish their role. This review will discuss established and emerging diagnostic tools and treatment options for CMV, including antiviral resistant CMV, in children undergoing haematopoietic stem cell transplant.

Citing Articles

Predicting cytomegalovirus infection and graft-versus-host disease using QuantiFERON-CMV and Monitor in pediatric transplants: a proof-of-concept study.

Souan L, Rihani R, Sughayer M Ther Adv Hematol. 2025; 16:20406207251316680.

PMID: 39926028 PMC: 11806478. DOI: 10.1177/20406207251316680.

Human Cytomegalovirus (HCMV) Genetic Diversity, Drug Resistance Testing and Prevalence of the Resistance Mutations: A Literature Review.

Grgic I, Gorenec L Trop Med Infect Dis. 2024; 9(2).

PMID: 38393138 PMC: 10892457. DOI: 10.3390/tropicalmed9020049.

References

Roy S, Kapoor A, Zhu F, Mukhopadhyay R, Ghosh A, Lee H . Artemisinins target the intermediate filament protein vimentin for human cytomegalovirus inhibition. J Biol Chem. 2020; 295(44):15013-15028. PMC: 7606667. DOI: 10.1074/jbc.RA120.014116. View

Ke P, Bao X, Zhou J, Li X, Zhuang J, He X . Donor CMV-specific cytotoxic T lymphocytes successfully treated drug-resistant cytomegalovirus encephalitis after allogeneic hematopoietic stem cell transplantation. Hematology. 2020; 25(1):43-47. DOI: 10.1080/16078454.2019.1710945. View

Sassine J, Khawaja F, Shigle T, Handy V, Foolad F, Aitken S . Refractory and Resistant Cytomegalovirus After Hematopoietic Cell Transplant in the Letermovir Primary Prophylaxis Era. Clin Infect Dis. 2021; 73(8):1346-1354. PMC: 8528390. DOI: 10.1093/cid/ciab298. View

DSouza A, Fretham C, Lee S, Arora M, Brunner J, Chhabra S . Current Use of and Trends in Hematopoietic Cell Transplantation in the United States. Biol Blood Marrow Transplant. 2020; 26(8):e177-e182. PMC: 7404814. DOI: 10.1016/j.bbmt.2020.04.013. View

John S, Yuzhakov O, Woods A, Deterling J, Hassett K, Shaw C . Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity. Vaccine. 2018; 36(12):1689-1699. DOI: 10.1016/j.vaccine.2018.01.029. View

Rowe R, Guo D, Lee M, Margossian S, London W, Lehmann L . Cytomegalovirus Infection in Pediatric Hematopoietic Stem Cell Transplantation: Risk Factors for Primary Infection and Cases of Recurrent and Late Infection at a Single Center. Biol Blood Marrow Transplant. 2016; 22(7):1275-1283. PMC: 5491305. DOI: 10.1016/j.bbmt.2016.04.004. View

Seckert C, Renzaho A, Reddehase M, Grzimek N . Hematopoietic stem cell transplantation with latently infected donors does not transmit virus to immunocompromised recipients in the murine model of cytomegalovirus infection. Med Microbiol Immunol. 2008; 197(2):251-9. DOI: 10.1007/s00430-008-0094-1. View

Muller C, Tilloy V, Frobert E, Feghoul L, Garrigue I, Lepiller Q . First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. Antiviral Res. 2022; 204:105361. DOI: 10.1016/j.antiviral.2022.105361. View

Teira P, Battiwalla M, Ramanathan M, Barrett A, Ahn K, Chen M . Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. Blood. 2016; 127(20):2427-38. PMC: 4874224. DOI: 10.1182/blood-2015-11-679639. View

10.

Waldman W, Knight D, Blinder L, Shen J, Lurain N, Miller D . Inhibition of cytomegalovirus in vitro and in vivo by the experimental immunosuppressive agent leflunomide. Intervirology. 2000; 42(5-6):412-8. DOI: 10.1159/000053979. View

11.

Chou S, Satterwhite L, Ercolani R . New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by Exposure to Letermovir and Ganciclovir. Antimicrob Agents Chemother. 2018; 62(9). PMC: 6125535. DOI: 10.1128/AAC.00922-18. View

12.

Sedlak R, Cook L, Cheng A, Magaret A, Jerome K . Clinical utility of droplet digital PCR for human cytomegalovirus. J Clin Microbiol. 2014; 52(8):2844-8. PMC: 4136144. DOI: 10.1128/JCM.00803-14. View

13.

McVoy M, Adler S . Human cytomegalovirus DNA replicates after early circularization by concatemer formation, and inversion occurs within the concatemer. J Virol. 1994; 68(2):1040-51. PMC: 236542. DOI: 10.1128/JVI.68.2.1040-1051.1994. View

14.

Limaye A, Corey L, Koelle D, Davis C, Boeckh M . Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet. 2000; 356(9230):645-9. DOI: 10.1016/S0140-6736(00)02607-6. View

15.

Iwasenko J, Scott G, Ziegler J, Rawlinson W . Emergence and persistence of multiple antiviral-resistant CMV strains in a highly immunocompromised child. J Clin Virol. 2007; 40(2):152-5. DOI: 10.1016/j.jcv.2007.07.003. View

16.

Shereck E, Cooney E, van de Ven C, Della-Lotta P, Cairo M . A pilot phase II study of alternate day ganciclovir and foscarnet in preventing cytomegalovirus (CMV) infections in at-risk pediatric and adolescent allogeneic stem cell transplant recipients. Pediatr Blood Cancer. 2006; 49(3):306-12. DOI: 10.1002/pbc.21043. View

17.

Cuevas-Ferrando E, Giron-Guzman I, Falco I, Perez-Cataluna A, Diaz-Reolid A, Aznar R . Discrimination of non-infectious SARS-CoV-2 particles from fomites by viability RT-qPCR. Environ Res. 2021; 203:111831. PMC: 8327643. DOI: 10.1016/j.envres.2021.111831. View

18.

Jaing T, Chang T, Chen S, Wen Y, Yu T, Lee C . Factors associated with cytomegalovirus infection in children undergoing allogeneic hematopoietic stem-cell transplantation. Medicine (Baltimore). 2019; 98(4):e14172. PMC: 6358375. DOI: 10.1097/MD.0000000000014172. View

19.

Okleberry K, Warren R, Smee D . Metabolism of ganciclovir and cidofovir in cells infected with drug-resistant and wild-type strains of murine cytomegalovirus. Antiviral Res. 1997; 35(2):83-90. DOI: 10.1016/s0166-3542(97)00013-2. View

20.

Kuhn A, Puttkammer J, Madigan T, Dinnes L, Khan S, Ferdjallah A . Letermovir as Cytomegalovirus Prophylaxis in a Pediatric Cohort: A Retrospective Analysis. Transplant Cell Ther. 2022; 29(1):62.e1-62.e4. DOI: 10.1016/j.jtct.2022.10.005. View